All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The anti-CD22 chimeric antigen receptor (CAR) Jurkat cell line is a stable cell line derived from anti-CD22 CAR lentivirus transduction. This transduced CAR lentiviral vector was constructed to express scFv of an anti-CD22 antibody linked to the CD28 and CD3ζ signaling domains. And this recombinant cell product can be used to target human CD22 and treat Acute lymphoblastic leukemia (ALL).
There are currently no customer reviews or questions for Anti-CD22 (Pinatuzumab) h(CD28-CD3ζ) CAR, Jurkat Cell (CARJ-ZP029). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION